Phylogica awarded three new peptide patents
Phylogica (ASX:PYC) has added three new patents to its portfolio, including one in Japan protecting its core technology.
The company has been awarded a Japanese patent covering “methods of constructing and screening libraries of peptide structure”, the company said.
This patent is similar to its patents in the US and Australia and covers methods of designing synthetic Phylomer peptide libraries based on the identification of parts of natural proteins.
Phylogica said the technology covered in the patents allows the company to choose from the most suitable structures found in nature for the shape of its Phylomer peptides to, for example, maximise stability. Synthetic Phylomer libraries are well suited to high-throughput screening applications.
The US Patent and Trademark Office has meanwhile granted the company two new patents in the US covering particular Phylomers relevant to inflammatory diseases.
One patent covers a set of peptides against targets including rheumatoid arthritis and inflammatory bowel disease, while the second is relevant to Phylomers that block lung inflammation in an animal model of acute respiratory distress syndrome (ARDS).
Phylogica (ASX:PYC) shares were trading 7.69% higher at $0.014 as of around 2 pm on Thursday.
A pre-emptive approach to treating leukaemia relapse
The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...
RNA-targeted therapy shows promise for childhood dementia
Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...
